{"nctId":"NCT00984295","briefTitle":"Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines","startDateStruct":{"date":"2000-06"},"conditions":["Measles","Mumps","Rubella","Varicella"],"count":1913,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Biological: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live","Biological: Comparator: Tripedia","Biological: Comparator: Comvax"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Biological: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live","Biological: Comparator: Tripedia","Biological: Comparator: Comvax"]},{"label":"3","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Comparator: Tripedia","Biological: Comparator: Comvax","Biological: Comparator: Varivax","Biological: Comparator: M-M-R II"]}],"interventions":[{"name":"Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live","otherNames":["ProQuad"]},{"name":"Comparator: Tripedia","otherNames":[]},{"name":"Comparator: Comvax","otherNames":[]},{"name":"Comparator: Varivax","otherNames":[]},{"name":"Comparator: M-M-R II","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* In good health\n* Negative clinical history of varicella, zoster, measles, mumps, rubella, diptheria, tetanus, pertussis, invasive Hib disease and hepatitis B\n* Had completed either a 2-dose primary series of PedvaxHIB or COMVAX or any 3-dose primary series of a licensed Hib vaccine\n* Had received 2 or 3 doses of any hepatitis B vaccine or COMVAX prior to entry into trial\n\nExclusion Criteria:\n\n* Previous receipt of measles, mumps, rubella or varicella vaccine either alone or in combination\n* Any immune impairment or deficiency\n* Recent household, daycare or school exposure to invasive Hib disease or hepatitis B\n* Exposure to measles, mumps, rubella, varicella, or zoster in the 4 weeks prior to vaccination\n* Vaccination with an inactive vaccine with in the past 14 days\n* Vaccination with a live vaccine within the past 30 days\n* Receipt of immune globulin, blood transfusion or blood-derived product in the past 3 months\n* Recent history of fever or underlying medical problems","healthyVolunteers":true,"sex":"ALL","minimumAge":"12 Months","maximumAge":"15 Months","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥120 mIU/mL","description":"Antibody Response to Measles at 6 Weeks Postvaccination for Participants Initially Seronegative (a titer \\<120 mIU/mL) to Measles at Baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"741","spread":null},{"groupId":"OG001","value":"383","spread":null},{"groupId":"OG002","value":"124","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Postvaccination Mumps ELISA Antibody Titer ≥10 Ab Units/mL","description":"Antibody Response to Mumps at 6 Weeks Postvaccination for Participants Initially Seronegative (a titer \\<10 Ab units/mL) to Mumps at Baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"774","spread":null},{"groupId":"OG001","value":"395","spread":null},{"groupId":"OG002","value":"143","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Postvaccination Rubella ELISA Antibody Titer ≥10 IU/mL","description":"Antibody Response to Rubella at 6 Weeks Postvaccination for Participants Initially Seronegative (a titer \\<10 IU/mL) to Rubella at Baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"817","spread":null},{"groupId":"OG001","value":"418","spread":null},{"groupId":"OG002","value":"148","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Postvaccination Varicella-Zoster Virus (VZV) Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Antibody Titer ≥5 gpELISA Units/mL","description":"Antibody Response to Varicella-Zoster Virus (VZV) at 6 Weeks Postvaccination for Participants Initially Seronegative (a titer \\<0.6 gpELISA units/mL) to VZV at Baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"679","spread":null},{"groupId":"OG001","value":"348","spread":null},{"groupId":"OG002","value":"130","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Postvaccination Diphtheria Vero Cell Culture Assay Antibody Titer ≥0.1 IU/mL","description":"Antibody response to Diphtheria at 6 weeks postvaccination","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"667","spread":null},{"groupId":"OG001","value":"333","spread":null},{"groupId":"OG002","value":"94","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Postvaccination Tetanus Enzyme Immunoassay (EIA) Antibody Titer ≥0.1 IU/mL","description":"Antibody response to Tetanus (tetanus antitoxin were measured with an indirect, noncompetitive enzyme immunoassay (EIA)) at 6 weeks postvaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"796","spread":null},{"groupId":"OG001","value":"386","spread":null},{"groupId":"OG002","value":"114","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With ≥4-fold Rise in Pertussis Toxin (PT) EIA Antibody Titer","description":"Antibody response to Pertussis Toxin (titers of pertussis toxin antibodies were measured with an indirect, noncompetitive EIA).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"554","spread":null},{"groupId":"OG001","value":"321","spread":null},{"groupId":"OG002","value":"56","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With ≥4-fold Rise in Pertussis Filamentous Hemagglutinin (FHA) EIA Antibody Titer","description":"Antibody response to pertussis FHA(titers of pertussis filamentous hemagglutinin antibodies were measured with an indirect, noncompetitive EIA).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"502","spread":null},{"groupId":"OG001","value":"309","spread":null},{"groupId":"OG002","value":"53","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Postvaccination Hepatitis B (Quantitative AUSAB™ Radioimmunoassay (RIA)) Antibody Titer ≥10 mIU/mL","description":"Antibody response to Hepatitis B (titers measured using the Quantitative AUSAB™ radioimmunoassay (RIA)).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"791","spread":null},{"groupId":"OG001","value":"391","spread":null},{"groupId":"OG002","value":"121","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Postvaccination Haemophilus Influenzae Type B (Hib) Radioimmunoassay (RIA) Antibody Titer ≥ 1 mcg/mL","description":"Antibody response to Haemophilus influenzae type B (Hib). (Anti-polyribosylribitol phosphate (PRP) was measured by radioimmunoassay (RIA) using radiolabeled-PRP according to a standard Farr technique and with a standard provided by the U.S. FDA.)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"778","spread":null},{"groupId":"OG001","value":"384","spread":null},{"groupId":"OG002","value":"119","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to Measles at 6 Weeks Postvaccination for Participants Initially Seronegative to Measles at Baseline - Geometric Mean Titer (GMT)","description":"Postvaccination Observed Geometric Mean Titer of Antibody to Measles. (Titers measured using Measles ELISA.)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3504.9","spread":null},{"groupId":"OG001","value":"3506.2","spread":null},{"groupId":"OG002","value":"2562.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to Mumps at 6 Weeks Postvaccination for Participants Initially Seronegative to Mumps at Baseline - GMT","description":"Postvaccination observed GMT of antibody to mumps. (Titers measured using mumps ELISA.)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.4","spread":null},{"groupId":"OG001","value":"84.1","spread":null},{"groupId":"OG002","value":"98.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to Rubella at 6 Weeks Postvaccination for Participants Initially Seronegative to Rubella at Baseline - GMT","description":"Postvaccination Observed Geometric Mean Titer of Antibody to Rubella. (Titers measured using Rubella ELISA.)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"99.9","spread":null},{"groupId":"OG002","value":"126.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to Varicella at 6 Weeks Postvaccination for Participants Initially Seronegative to Varicella at Baseline - GMT","description":"Postvaccination Observed Geometric Mean Titer of Antibody to Varicella. (Titers measured using VZV gpELISA.)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":null},{"groupId":"OG001","value":"15.4","spread":null},{"groupId":"OG002","value":"15.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to Diphtheria at 6 Weeks Postvaccination - GMT","description":"Postvaccination Observed Geometric Mean Titer of Antibody to Diphtheria. (Titers measured using Vero Cell Culture Assay.)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.33","spread":null},{"groupId":"OG001","value":"1.72","spread":null},{"groupId":"OG002","value":"1.59","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to Pertussis Toxin (PT) at 6 Weeks Postvaccination - GMT","description":"Postvaccination Observed Geometric Mean Titer of Antibody to Pertussis Toxin (PT). Titers measured using an indirect, noncompetitive Pertussis enzyme immunoassay (EIA).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null},{"groupId":"OG001","value":"55.7","spread":null},{"groupId":"OG002","value":"46.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to Pertussis Filamentous Hemagglutinin (FHA) at 6 Weeks Postvaccination - GMT","description":"Postvaccination Observed Geometric Mean Titer of Antibody to Pertussis Filamentous Hemagglutinin (FHA). (Titers measured using an indirect, noncompetitive Pertussis enzyme immunoassay (EIA).)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.1","spread":null},{"groupId":"OG001","value":"81.2","spread":null},{"groupId":"OG002","value":"65.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to Hepatitis B at 6 Weeks Postvaccination - GMT","description":"Postvaccination Observed Geometric Mean Titer of Antibody to Hepatitis B. (Titers measured using the Quantitative AUSAB™ radioimmunoassay (RIA).)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"758","spread":null},{"groupId":"OG001","value":"996","spread":null},{"groupId":"OG002","value":"1135","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to Haemophilus Influenzae Type B (Hib) at 6 Weeks Postvaccination - GMT","description":"Postvaccination observed GMT of antibody to Hib. (Anti-polyribosylribitol phosphate (PRP) was measured by RIA using radiolabeled-PRP according to a standard Farr technique and with a standard provided by the U.S. FDA.)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":null},{"groupId":"OG001","value":"12.1","spread":null},{"groupId":"OG002","value":"12.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Antibody Response to Tetanus at 6 Weeks Postvaccination - GMT","description":"Postvaccination Observed Geometric Mean Titer of Antibody to Tetanus. (Titers of tetanus antitoxin were measured with an indirect, noncompetitive enzyme immunoassay (EIA).)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.93","spread":null},{"groupId":"OG001","value":"5.74","spread":null},{"groupId":"OG002","value":"4.36","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":929},"commonTop":["Pain/Tenderness/Soreness (Comvax Injection-site)","Pain/Tenderness/Soreness (Tripedia Injection-site)","Fever","Infection, Respiratory, Upper","Erythema (Comvax Injection-site)"]}}}